Australian Govt Needs To Tackle Low Biosimilar Awareness And Switching Concerns
This article was originally published in SRA
The Australian government is facing something of an uphill struggle in convincing patients and healthcare professionals of the benefits of biosimilars, at least judging by a survey that has just been presented to the stakeholder reference group set up to advise on the government's biosimilar awareness strategy1.
You may also be interested in...
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.
Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir
The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.